Despite the availability of effective therapies, the majority of patients with hypertension have poor blood pressure control. Key advances in 2023 have the potential to lead to better treatment adherence and control of blood pressure as well as providing new understanding of postmenopausal hypertension, which may lead to improved therapies.
Key advances
-
Inaccurate data from a smart wearable cuffless blood pressure device highlights the need to validate such devices to prevent misleading measurements and realize their potential to provide valuable information on beat-to-beat blood pressure2
-
A single dose of the small-interfering RNA zilebesiran resulted in a decrease in blood pressure that was sustained for 24 weeks3
-
Ten-year follow-up data continue to demonstrate a sustained blood-pressure lowering effect of catheter-based renal denervation in patients with resistant hypertension4,5
-
Among postmenopausal women using oestrogen-only hormone replacement therapy, non-oral oestrogen administered at the lowest dose for the shortest time period was associated with the lowest risk of hypertension7
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Touyz, R. M. & Harrison, D. G. Hope for resistant hypertension through BrigHTN and PRECISION. Nat. Rev. Nephrol. 19, 216–217 (2023).
Tan, I. et al. Evaluation of the ability of a commercially available cuffless wearable device to track blood pressure changes. J. Hypertens. 41, 1003–1010 (2023).
Desai, A. S. et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N. Engl. J. Med. 389, 228–238 (2023).
Sesa-Ashton, G. et al. Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension. Hypertension 80, 811–819 (2023).
Mahfoud, F. et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: subgroup analysis of the global SYMPLICITY registry DEFINE. Hypertension 80, 1759–1770 (2023).
Singh, R. R. et al. Sustained decrease in blood pressure and reduced anatomical and functional reinnervation of renal nerves in hypertensive sheep 30 months after catheter-based renal denervation. Hypertension 73, 718–727 (2019).
Kalenga, C. Z. et al. Association between the route of administration and formulation of estrogen therapy and hypertension risk in postmenopausal women: a prospective population-based study. Hypertension 80, 1463–1473 (2023).
Virwani, P. D. et al. Sex differences in association between gut microbiome and essential hypertension based on ambulatory blood pressure monitoring. Hypertension 80, 1331–1342 (2023).
Kresovich, J. K. et al. Peripheral immune cell composition is altered in women before and after a hypertension diagnosis. Hypertension 80, 43–53 (2023).
Peripheral circulation: the importance of neural control. ilearn.med.monash.edu.au https://ilearn.med.monash.edu.au/physiology/cardiovascular/ (Faculty of Medicine, Nursing and Health Sciences, Monash University, 2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Denton, K.M. Progress towards improving blood pressure control. Nat Rev Nephrol 20, 73–74 (2024). https://doi.org/10.1038/s41581-023-00798-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-023-00798-7
